Flagship Ventures Fund Iv General Partner Llc - Net Worth and Insider Trading

Flagship Ventures Fund Iv General Partner Llc Net Worth

The estimated net worth of Flagship Ventures Fund Iv General Partner Llc is at least $547 dollars as of 2024-06-01. Flagship Ventures Fund Iv General Partner Llc is the 10% Owner of Evelo Biosciences Inc and owns about 911,670 shares of Evelo Biosciences Inc (EVLO) stock worth over $547. Details can be seen in Flagship Ventures Fund Iv General Partner Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Flagship Ventures Fund Iv General Partner Llc has not made any transactions after 2018-05-11 and currently still holds the listed stock(s).

Transaction Summary of Flagship Ventures Fund Iv General Partner Llc

Flagship Ventures Fund Iv General Partner Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Flagship Ventures Fund Iv General Partner Llc owns 12 companies in total, including Moderna Inc (MRNA) , Evelo Biosciences Inc (EVLO) , and Kaleido Biosciences Inc (KLDO) among others .

Click here to see the complete history of Flagship Ventures Fund Iv General Partner Llc’s form 4 insider trades.

Insider Ownership Summary of Flagship Ventures Fund Iv General Partner Llc

Ticker	Comapny	Transaction Date	Type of Owner
MRNA	Moderna Inc	2018-12-07	director & 10 percent owner
EVLO	Evelo Biosciences Inc	2018-05-11	10 percent owner
KLDO	Kaleido Biosciences Inc	2019-02-27	director & 10 percent owner
		2020-05-18	10 percent owner
		2019-05-01	10 percent owner
		2021-03-19	10 percent owner
		2017-08-17	10 percent owner
		2016-09-06	10 percent owner
		2016-08-11	10 percent owner
		2020-11-23	10 percent owner
		2014-08-06	10 percent owner
		2016-09-06	10 percent owner

Flagship Ventures Fund Iv General Partner Llc Latest Holdings Summary

Flagship Ventures Fund Iv General Partner Llc currently owns a total of 1 stock. Flagship Ventures Fund Iv General Partner Llc owns 911,670 shares of Evelo Biosciences Inc (EVLO) as of May 11, 2018, with a value of $547.

Latest Holdings of Flagship Ventures Fund Iv General Partner Llc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
EVLO	Evelo Biosciences Inc	2018-05-11	911,670	0.00	547

Holding Weightings of Flagship Ventures Fund Iv General Partner Llc

Flagship Ventures Fund Iv General Partner Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Flagship Ventures Fund Iv General Partner Llc has made a total of 0 transactions in Evelo Biosciences Inc (EVLO) over the past 5 years. The most-recent trade in Evelo Biosciences Inc is the acquisition of 14,063 shares on May 11, 2018, which cost Flagship Ventures Fund Iv General Partner Llc around $5 Million.

Insider Trading History of Flagship Ventures Fund Iv General Partner Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Flagship Ventures Fund Iv General Partner Llc Trading Performance

GuruFocus tracks the stock performance after each of Flagship Ventures Fund Iv General Partner Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Flagship Ventures Fund Iv General Partner Llc is -17.94%. GuruFocus also compares Flagship Ventures Fund Iv General Partner Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Flagship Ventures Fund Iv General Partner Llc within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Flagship Ventures Fund Iv General Partner Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Flagship Ventures Fund Iv General Partner Llc

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-13.13
Relative Return to S&P 500(%)	-15.12

Flagship Ventures Fund Iv General Partner Llc Ownership Network

Ownership Network List of Flagship Ventures Fund Iv General Partner Llc

No Data

Ownership Network Relation of Flagship Ventures Fund Iv General Partner Llc

Flagship Ventures Fund Iv General Partner Llc Owned Company Details

What does Moderna Inc do?

Who are the key executives at Moderna Inc?

Flagship Ventures Fund Iv General Partner Llc is the director & 10 percent owner of Moderna Inc. Other key executives at Moderna Inc include Chief Financial Officer James M Mock , director & 10 percent owner Noubar Afeyan , and Chief Legal Officer Shannon Thyme Klinger .

Moderna Inc (MRNA) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Moderna Inc (MRNA). Other recent insider transactions involving Moderna Inc (MRNA) include a net sale of 600,000 shares made by Noubar Afeyan , a net sale of 2,253,506 shares made by Stephane Bancel , and a net sale of 170,297 shares made by Stephen Hoge .

In summary, during the past 3 months, insiders sold 219,581 shares of Moderna Inc (MRNA) in total and bought 0 shares, with a net sale of 219,581 shares. During the past 18 months, 3,046,252 shares of Moderna Inc (MRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,046,252 shares.

Moderna Inc (MRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Moderna Inc Insider Transactions

No Available Data

What does Evelo Biosciences Inc do?

Who are the key executives at Evelo Biosciences Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Evelo Biosciences Inc. Other key executives at Evelo Biosciences Inc include Chief Financial Officer Marella Thorell , Chief Medical Officer Duncan Mchale , and See Remarks Mark Bodmer .

Evelo Biosciences Inc (EVLO) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Evelo Biosciences Inc (EVLO). Other recent insider transactions involving Evelo Biosciences Inc (EVLO) include a net sale of 103,730 shares made by Mark Bodmer , a net sale of 80,121 shares made by Duncan Mchale , and a net sale of 46,345 shares made by Marella Thorell .

In summary, during the past 3 months, insiders sold 0 shares of Evelo Biosciences Inc (EVLO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 46,837 shares of Evelo Biosciences Inc (EVLO) were sold and 5,411,255 shares were bought by its insiders, resulting in a net purchase of 5,364,418 shares.

Evelo Biosciences Inc (EVLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Evelo Biosciences Inc Insider Transactions

No Available Data

What does Kaleido Biosciences Inc do?

Who are the key executives at Kaleido Biosciences Inc?

Flagship Ventures Fund Iv General Partner Llc is the director & 10 percent owner of Kaleido Biosciences Inc. Other key executives at Kaleido Biosciences Inc include Chief Medical Officer Alison S Long , Chief Scientific Officer Van Hylckama Vlieg Johan , and 10 percent owner Flagship Ventures Fund Iv, L.p. .

Kaleido Biosciences Inc (KLDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kaleido Biosciences Inc (KLDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kaleido Biosciences Inc (KLDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kaleido Biosciences Inc (KLDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kaleido Biosciences Inc Insider Transactions

No Available Data

What does Axcella Health Inc do?

Who are the key executives at Axcella Health Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Axcella Health Inc. Other key executives at Axcella Health Inc include Senior Vice President & CIPO Paul Fehlner , director & President and CEO William Hinshaw , and 10 percent owner L.p. Fpa, .

Axcella Health Inc (AXLA) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Axcella Health Inc (AXLA). Other recent insider transactions involving Axcella Health Inc (AXLA) include a net sale of 5,221 shares made by Paul Fehlner ,

In summary, during the past 3 months, insiders sold 0 shares of Axcella Health Inc (AXLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 209 shares of Axcella Health Inc (AXLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 209 shares.

Axcella Health Inc (AXLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axcella Health Inc Insider Transactions

No Available Data

What does TransMedics Group Inc do?

Who are the key executives at TransMedics Group Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of TransMedics Group Inc. Other key executives at TransMedics Group Inc include Chief Financial Officer Stephen Gordon , director & President & CEO Waleed H Hassanein , and See Remarks Nicholas Corcoran .

TransMedics Group Inc (TMDX) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in TransMedics Group Inc (TMDX). Other recent insider transactions involving TransMedics Group Inc (TMDX) include a net sale of 308,452 shares made by Tamer I Khayal , a net sale of 265,569 shares made by Waleed H Hassanein , and a net sale of 106,903 shares made by Stephen Gordon .

In summary, during the past 3 months, insiders sold 409,561 shares of TransMedics Group Inc (TMDX) in total and bought 0 shares, with a net sale of 409,561 shares. During the past 18 months, 818,547 shares of TransMedics Group Inc (TMDX) were sold and 2,500 shares were bought by its insiders, resulting in a net sale of 816,047 shares.

TransMedics Group Inc (TMDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

TransMedics Group Inc Insider Transactions

No Available Data

What does Rubius Therapeutics Inc do?

Who are the key executives at Rubius Therapeutics Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Rubius Therapeutics Inc. Other key executives at Rubius Therapeutics Inc include CEO and President Dannielle Appelhans , director & Chief Executive Officer Pablo J Cagnoni , and Chief Scientific Officer Laurence A. Turka .

Rubius Therapeutics Inc (RUBY) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Rubius Therapeutics Inc (RUBY). Other recent insider transactions involving Rubius Therapeutics Inc (RUBY) include a net sale of 15,688 shares made by Pablo J Cagnoni , a net sale of 14,263 shares made by Dannielle Appelhans , and a net sale of 2,593 shares made by Laurence A. Turka .

In summary, during the past 3 months, insiders sold 0 shares of Rubius Therapeutics Inc (RUBY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 32,544 shares of Rubius Therapeutics Inc (RUBY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 32,544 shares.

Rubius Therapeutics Inc (RUBY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rubius Therapeutics Inc Insider Transactions

No Available Data

What does Syros Pharmaceuticals Inc do?

Who are the key executives at Syros Pharmaceuticals Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include Chief Medical Officer David Roth , Chief Scientific Officer Eric R Olson , and Chief Financial Officer Jason Haas .

Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 30,523 shares made by David Roth , a net purchase of 904,977 shares made by Srinivas Akkaraju , and a net sale of 689 shares made by Eric R Olson .

In summary, during the past 3 months, insiders sold 10,601 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 0 shares, with a net sale of 10,601 shares. During the past 18 months, 31,212 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 904,977 shares were bought by its insiders, resulting in a net purchase of 873,765 shares.

Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syros Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sesen Bio Inc do?

Who are the key executives at Sesen Bio Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Sesen Bio Inc. Other key executives at Sesen Bio Inc include 10 percent owner Modernatx, Inc. , director & President and CEO Steven Kelly , and Chief Financial Officer Richard Steven Morris .

Sesen Bio Inc (SESN) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Sesen Bio Inc (SESN). Other recent insider transactions involving Sesen Bio Inc (SESN) include a net sale of 541,214 shares made by Thomas R Cannell , a net sale of 407,711 shares made by Monica Forbes , and a net sale of 259,049 shares made by Mark Sullivan .

In summary, during the past 3 months, insiders sold 0 shares of Sesen Bio Inc (SESN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 71,436 shares of Sesen Bio Inc (SESN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 71,436 shares.

Sesen Bio Inc (SESN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sesen Bio Inc Insider Transactions

No Available Data

What does Editas Medicine Inc do?

Who are the key executives at Editas Medicine Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Editas Medicine Inc. Other key executives at Editas Medicine Inc include EVP & CHIEF FINANCIAL OFFICER Erick Lucera , director & CEO Gilmore Neil O'neill , and SVP & CHIEF MEDICAL OFFICER Baisong Mei .

Editas Medicine Inc (EDIT) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 6,647 shares made by Bruce Eaton , a net sale of 7,365 shares made by Michelle Robertson , and a net sale of 84,310 shares made by Gilmore Neil O'neill .

In summary, during the past 3 months, insiders sold 120,488 shares of Editas Medicine Inc (EDIT) in total and bought 45,000 shares, with a net sale of 75,488 shares. During the past 18 months, 148,093 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 103,093 shares.

Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Editas Medicine Inc Insider Transactions

No Available Data

What does Seres Therapeutics Inc do?

Who are the key executives at Seres Therapeutics Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of Seres Therapeutics Inc. Other key executives at Seres Therapeutics Inc include Chief Scientific Officer Matthew R. Henn , CFO and EVP Eric D. Shaff , and See Remarks Thomas Desrosier .

Seres Therapeutics Inc (MCRB) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in Seres Therapeutics Inc (MCRB). Other recent insider transactions involving Seres Therapeutics Inc (MCRB) include a net sale of 17,204 shares made by David S. Ege , a net sale of 22,536 shares made by Eric D. Shaff , and a net sale of 9,571 shares made by Moltke Lisa Von .

In summary, during the past 3 months, insiders sold 6,901 shares of Seres Therapeutics Inc (MCRB) in total and bought 0 shares, with a net sale of 6,901 shares. During the past 18 months, 85,089 shares of Seres Therapeutics Inc (MCRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 85,089 shares.

Seres Therapeutics Inc (MCRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seres Therapeutics Inc Insider Transactions

No Available Data

What does T2 Biosystems Inc do?

Who are the key executives at T2 Biosystems Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of T2 Biosystems Inc. Other key executives at T2 Biosystems Inc include 10 percent owner Cr Group L.p. , 10 percent owner Crg Partners Iii (cayman) Unlev Aiv I L.p. , and 10 percent owner Crg Partners Iii (cayman) Lev Aiv I L.p. .

T2 Biosystems Inc (TTOO) Insider Trades Summary

Over the past 18 months, Flagship Ventures Fund Iv General Partner Llc made no insider transaction in T2 Biosystems Inc (TTOO). Other recent insider transactions involving T2 Biosystems Inc (TTOO) include a net sale of 48,345,798 shares made by Cr Group L.p. , a net sale of 3,969 shares made by Michael Terrence Gibbs , and a net sale of 1,074 shares made by Brett A. Giffin .

In summary, during the past 3 months, insiders sold 0 shares of T2 Biosystems Inc (TTOO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 48,363,307 shares of T2 Biosystems Inc (TTOO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 48,363,307 shares.

T2 Biosystems Inc (TTOO)'s detailed insider trading history can be found in Insider Trading Tracker table.

T2 Biosystems Inc Insider Transactions

No Available Data

What does CARISMA Therapeutics Inc do?

Who are the key executives at CARISMA Therapeutics Inc?

Flagship Ventures Fund Iv General Partner Llc is the 10 percent owner of CARISMA Therapeutics Inc. Other key executives at CARISMA Therapeutics Inc include 10 percent owner Modernatx, Inc. , director & President and CEO Steven Kelly , and Chief Financial Officer Richard Steven Morris .

CARISMA Therapeutics Inc (CARM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CARISMA Therapeutics Inc (CARM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CARISMA Therapeutics Inc (CARM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CARISMA Therapeutics Inc (CARM)'s detailed insider trading history can be found in Insider Trading Tracker table.

CARISMA Therapeutics Inc Insider Transactions

No Available Data

Flagship Ventures Fund Iv General Partner Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Flagship Ventures Fund Iv General Partner Llc. You might contact Flagship Ventures Fund Iv General Partner Llc via mailing address: 55 Cambridge Parkway, Suite 800e, Cambridge Ma 02142.

Discussions on Flagship Ventures Fund Iv General Partner Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.